Non-small-cell lung cancer
Conditions
Interventions
Carboplatin+Pemetrexed
Sponsors
Tochigi Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically confirmed Stage 3B/4 non-small-cell lung cancer and non-squamous cell carcinoma. 2.No prior chemotherapy. 3.With one or more measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) ver1.1 4.Age 20<=, <=75 5.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. 6.Adequate function of vital organs, including normal hematopoietic function, normal liver function and normal renal function. 7.A life expectancy of more than 3 months. 8.All patients provided written informed consent before initiation of study-related procedures.
Exclusion criteria
Exclusion criteria: 1.Symptomatic Brain metastasis. 2.History of active double cancer. 3.Severe infection 4.Severe comorbidity (heart failure tendency to hemorrhages, uncontrollable hypertension, uncontrollable diabetes, etc) 5.Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 6.With a history of drug sensitivity. 7.Pregnant or lactating women or those who declined contraception. 8.Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival Safety Progression free survival | — |
Countries
Japan
Contacts
Public ContactTakashi Kasai
Tochigi Cancer Center Division of Thoracic Oncology
Outcome results
None listed